Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fostroxacitabine Bralpamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medivir's Fostrox + Lenvima Shows Promise In Liver Cancer
    Medivir's Fostrox + Lenvima Shows Promise In Liver Cancer

    16 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivirs-fostrox--lenvima-confirm-promise-of-improved-outcomes-in-advanced-liver-cancer-detailed-and-mature-data-presented-at-esmo-302248817.html

    PR NEWSWIRE
    16 Sep 2024
    Share Share
    Fostrox + Lenvima® holds promise of greatly improved outcomes
    Fostrox + Lenvima® holds promise of greatly improved outcomes

    27 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fostrox--lenvima-holds-promise-of-greatly-improved-outcomes-for-advanced-liver-cancer-patients-reveals-new-data-from-medivir-at-esmo-gi-302184220.html

    PR NEWSWIRE
    27 Jun 2024
    Share Share
    Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima
    Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima

    19 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-selects-global-cro-partner-for-upcoming-phase-2b-study-in-hcc-with-fostrox--lenvima-and-initiates-study-feasibility-302176636.html

    PR NEWSWIRE
    19 Jun 2024
    Share Share
    Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI
    Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI

    29 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html

    PR NEWSWIRE
    29 Apr 2024
    Share Share
    Medivir presents data on additive activity of fostrox with Lenvima or sorafenib
    Medivir presents data on additive activity of fostrox with Lenvima or sorafenib

    07 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-presents-data-on-additive-activity-of-fostrox-in-combination-with-lenvima-or-sorafenib-in-non-clinical-tumor-models-at-ilca-301920306.html

    PR NEWSWIRE
    07 Sep 2023
    Share Share
    Medivir reports promising interim data
    Medivir reports promising interim data

    04 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-reports-promising-interim-data-including-a-first-complete-response-in-phase-1b2a-hcc-study-with-fostrox-in-combination-with-lenvima-301916719.html

    PR NEWSWIRE
    04 Sep 2023
    Share Share